Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific has demonstrated robust growth across several product lines, with Watchman sales increasing by 35% year-over-year and electrophysiology (EP) experiencing a striking 63% growth, indicative of strong market demand and competitive positioning. The company's guidance for Q4 suggests organic sales growth of 11-13%, coupled with expected GAAP EPS of $0.48-$0.52, reflecting a solid financial outlook driven by effective product adoption and a diversified portfolio. Additionally, significant future contributions are anticipated from growth areas such as Nalu, projected to surpass $60 million in sales by 2025, along with continued expansion in coronary therapies and diagnostics, bolstering a positive long-term growth trajectory.

Bears say

Boston Scientific is facing a challenging financial environment marked by anticipated foreign exchange headwinds of approximately $0.04 for the full year, indicating potential revenue pressure. The firm's reliance on mature markets within its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, coupled with pricing pressures, raises concerns about sustained growth as sales may struggle to meet internal and consensus expectations. Additionally, the company's revenue performance has shown mixed results, with significant setbacks in key segments such as Urology and Interventional Cardiology, which may hinder its future growth trajectory if product integrations do not proceed smoothly.

Boston Scientific (BSX) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 17 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.